OR WAIT null SECS
Arthrex to receive US rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sports medicine
Celularity Inc., a clinical-stage biotechnology company that develops cell therapies and biomaterial products derived from the postpartum human placenta to treat cancer, infectious and degenerative diseases, and Arthrex, Inc., a specialist in minimally invasive orthopedic technology, have entered into an exclusive partnership to distribute and commercialize Celularity’s biomaterial products for orthopedic surgery and sports medicine.
Under the terms of the agreement, NJ-based Celularity will provide Arthrex with exclusive commercial distribution rights for orthopedic surgery and sports medicine and will continue to be responsible for product manufacturing and supply.
“We are tremendously excited to have Arthrex, a global leader in minimally invasive orthopedics, as a commercial partner to distribute our placental-derived biomaterial products,” said Robert J. Hariri, MD, PhD., founder, chairperson and CEO of Celularity. “Each of our regenerative products leverages the unique properties of the placenta to augment the body’s innate ability to heal across a variety of clinical conditions. We look forward to working closely with Arthrex to increase the availability of these innovative products in orthopedic surgery and sports medicine, and to improve the lives of patients.”
The partnership hopes to broaden the platform for using Celularity’s regenerative products in the orthopedic surgery market, which some estimates have totaling $1.5 billion in the US.
Arthrex is headquartered in Naples, FL. The company has expertise in orthopedic surgical device design, research, manufacturing and medical education.